Oleoylethanolamide supplementation in women with the poly cystic ovarian syndrome

Survey the effect of oleoylethanolamide on fasting blood sugar level, insulin resistance, lipid profile, oxidative stress status, inflammatory factors, sex hormones levels and anti-Mullerian hormone in women with poly cystic ovarian syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141025019669N20

Enrollment

Registered

2022-01-09

Start date

2022-01-15

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poly cystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Oleoylethanolamide, a capsule 200 mg per daily for two months, Manufacturer: Supplement Spot. Intervention 2: Control group: A daily placebo capsule containing whea

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: The patients who are 18-45 years old diagnosed with the poly cystic ovarian syndrome Having at least two criteria from Rotterdam's three criteria to diagnose this syndrome; BMI of less than 30 Signed consent by the patient

Exclusion criteria

Exclusion criteria: Pregnancy; lactation and menopause; Infectious disease; inflammatory disease; Cushing's syndrome; adrenal gland tumor; hypothyroidism; increased prolactinemia; acromegaly; diabetes and cancer; Hormone therapy over the past three months; Taking antioxidant supplements over the past three months, Drug use over the past three months includes contraceptives; glucocorticoids; lipid-lowering drugs and weight loss drugs.

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin resistance. Timepoint: Before the intervention and after the intervention. Method of measurement: Using the formula.;Lipid profile. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Inflammatory factors. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Sex hormones include FSH, LH and testosterone. Timepoint: Before intervention and after intervention. Method of measurement: Eliza.;Anti-Müllerian hormone. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Sleep quality. Timepoint: Before intervention and after intervention. Method of measurement: Petersburg’s sleep quality questionnaire.	—

Measure

Time frame

Fasting blood sugar. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin resistance. Timepoint: Before the intervention and after the intervention. Method of measurement: Using the formula.;Lipid profile. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Inflammatory factors. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Sex hormones include FSH, LH and testosterone. Timepoint: Before intervention and after intervention. Method of measurement: Eliza.;Anti-Müllerian hormone. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Sleep quality. Timepoint: Before intervention and after intervention. Method of measurement: Petersburg’s sleep quality questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Khadem Haghighian

Qazvin University of Medical Sciences

khademnut@yahoo.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026